IL239280A0 - Oral transmucosal transmission of glatiramer acetate - Google Patents
Oral transmucosal transmission of glatiramer acetateInfo
- Publication number
- IL239280A0 IL239280A0 IL239280A IL23928015A IL239280A0 IL 239280 A0 IL239280 A0 IL 239280A0 IL 239280 A IL239280 A IL 239280A IL 23928015 A IL23928015 A IL 23928015A IL 239280 A0 IL239280 A0 IL 239280A0
- Authority
- IL
- Israel
- Prior art keywords
- glatiramer acetate
- transmucosal delivery
- transmucosal
- delivery
- glatiramer
- Prior art date
Links
- 108010072051 Glatiramer Acetate Proteins 0.000 title 1
- FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 title 1
- 229960003776 glatiramer acetate Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Nutrition Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261745226P | 2012-12-21 | 2012-12-21 | |
| PCT/US2013/077034 WO2014100639A1 (en) | 2012-12-21 | 2013-12-20 | Transmucosal delivery of glatiramer acetate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL239280A0 true IL239280A0 (en) | 2015-07-30 |
Family
ID=50979257
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL239280A IL239280A0 (en) | 2012-12-21 | 2015-06-08 | Oral transmucosal transmission of glatiramer acetate |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20160193276A1 (enExample) |
| EP (1) | EP2934492A4 (enExample) |
| JP (1) | JP2016503803A (enExample) |
| KR (1) | KR20150111918A (enExample) |
| CN (1) | CN104869983A (enExample) |
| AU (1) | AU2013361053A1 (enExample) |
| BR (1) | BR112015014095A2 (enExample) |
| CA (1) | CA2895359A1 (enExample) |
| EA (1) | EA201591188A1 (enExample) |
| HK (2) | HK1214523A1 (enExample) |
| IL (1) | IL239280A0 (enExample) |
| MX (1) | MX2015007678A (enExample) |
| SG (1) | SG11201504422XA (enExample) |
| WO (1) | WO2014100639A1 (enExample) |
| ZA (1) | ZA201505049B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2627669T3 (pl) | 2010-10-11 | 2017-02-28 | Teva Pharmaceutical Industries Ltd. | Biomarkery cytokinowe jako biomarkery prognostyczne odpowiedzi klinicznej na octan glatirameru |
| EP2765857A4 (en) | 2011-10-10 | 2015-12-09 | Teva Pharma | SIMPLE NUCLEOTIDE POLYMORPHISMS USEFUL FOR PREDICTING CLINICAL RESPONSE TO GLATIRAMERATE ACETATE |
| UY35790A (es) | 2013-10-21 | 2015-05-29 | Teva Pharma | Marcadores genéticos que predicen la respuesta al acetato de glatiramer |
| WO2015140790A1 (en) | 2014-03-17 | 2015-09-24 | Mapi Pharma Ltd. | Sublingual delivery of glatiramer acetate |
| CN106924175B (zh) * | 2015-12-29 | 2020-07-03 | 深圳翰宇药业股份有限公司 | 一种治疗多发性硬化症的药物组合物 |
| WO2017138645A1 (ja) * | 2016-02-12 | 2017-08-17 | テイカ製薬株式会社 | 乾式造粒物及び該乾式造粒物を含有する固形製剤並びにそれらの製造方法 |
| WO2019002228A1 (en) | 2017-06-26 | 2019-01-03 | Institut Pasteur | TREATMENTS TO REMOVE HIV RESERVOIRS AND REDUCE VIRAL LOAD |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA200206457B (en) * | 2000-02-18 | 2003-08-13 | Yeda Res & Dev | Oral, nasal and pulmonary dosage formulations of copolymer 1. |
| EP1261361B1 (en) * | 2000-02-18 | 2006-06-14 | Yeda Research And Development Company, Ltd. | Oral, nasal and pulmonary dosage formulations of copolymer 1 (glatiramer acetate) |
| IL159715A0 (en) * | 2001-07-10 | 2004-06-20 | Teva Pharma | Drug delivery system for zero order, zero order-biphasic, ascending or descending drug delivery |
| PT1848415E (pt) * | 2005-02-17 | 2013-06-27 | Teva Pharma | Terapia de combinação com acetato de glatirâmero e rasagilina para o tratamento da esclerose múltipla |
| CN101312714A (zh) * | 2005-11-22 | 2008-11-26 | 特瓦制药工业有限公司 | 替米沙坦的药用组合物 |
| WO2007074472A2 (en) * | 2005-12-27 | 2007-07-05 | Jubilant Organosys Limited | Mouth dissolving pharmaceutical composition and process for preparing the same using a high amount of silicon dioxide |
| EA018573B1 (ru) * | 2006-09-22 | 2013-09-30 | Фармасайкликс, Инк. | Ингибиторы тирозинкиназы брутона |
| ES2329327B1 (es) * | 2008-03-19 | 2010-09-17 | Proyecto De Biomedicina Cima, S.L. | Combinaciones sinergicas de 5'-metiltioadenosina. |
-
2013
- 2013-12-20 US US14/653,022 patent/US20160193276A1/en not_active Abandoned
- 2013-12-20 SG SG11201504422XA patent/SG11201504422XA/en unknown
- 2013-12-20 JP JP2015549792A patent/JP2016503803A/ja not_active Withdrawn
- 2013-12-20 HK HK16102544.9A patent/HK1214523A1/zh unknown
- 2013-12-20 EP EP13865051.0A patent/EP2934492A4/en not_active Withdrawn
- 2013-12-20 WO PCT/US2013/077034 patent/WO2014100639A1/en not_active Ceased
- 2013-12-20 CN CN201380067083.XA patent/CN104869983A/zh active Pending
- 2013-12-20 BR BR112015014095A patent/BR112015014095A2/pt not_active IP Right Cessation
- 2013-12-20 AU AU2013361053A patent/AU2013361053A1/en not_active Abandoned
- 2013-12-20 EA EA201591188A patent/EA201591188A1/ru unknown
- 2013-12-20 KR KR1020157019729A patent/KR20150111918A/ko not_active Withdrawn
- 2013-12-20 HK HK16102020.2A patent/HK1214134A1/zh unknown
- 2013-12-20 CA CA2895359A patent/CA2895359A1/en not_active Abandoned
- 2013-12-20 MX MX2015007678A patent/MX2015007678A/es unknown
-
2015
- 2015-06-08 IL IL239280A patent/IL239280A0/en unknown
- 2015-07-14 ZA ZA2015/05049A patent/ZA201505049B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014100639A1 (en) | 2014-06-26 |
| BR112015014095A2 (pt) | 2017-07-11 |
| CN104869983A (zh) | 2015-08-26 |
| EP2934492A1 (en) | 2015-10-28 |
| HK1214523A1 (zh) | 2016-07-29 |
| SG11201504422XA (en) | 2015-07-30 |
| CA2895359A1 (en) | 2014-06-26 |
| US20160193276A1 (en) | 2016-07-07 |
| EA201591188A1 (ru) | 2016-04-29 |
| HK1214134A1 (zh) | 2016-07-22 |
| MX2015007678A (es) | 2015-09-07 |
| KR20150111918A (ko) | 2015-10-06 |
| JP2016503803A (ja) | 2016-02-08 |
| ZA201505049B (en) | 2016-10-26 |
| EP2934492A4 (en) | 2016-08-17 |
| AU2013361053A1 (en) | 2015-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201502352B (en) | Liposomal drug delivery system | |
| IL236268B (en) | Preparations for mucosal administration and their uses | |
| EP2836982A4 (en) | DIGITAL CONTENT DELIVERANCE | |
| GB201215193D0 (en) | Order delivery system | |
| PL3313083T3 (pl) | Dostarczanie treści segmentowanej przestrzennie | |
| HUE062316T2 (hu) | Gyógyszer-adagolási technológia | |
| EP2830693A4 (en) | NARCOSEGAS DELIVERY SYSTEM | |
| ZA201504191B (en) | Transmucosal delivery of tocotrienol | |
| GB201213491D0 (en) | Content delivery system | |
| ZA201309156B (en) | Drug delivery system | |
| ZA201505049B (en) | Transmucosal delivery of glatiramer acetate | |
| SG11201404123XA (en) | Medicament delivery devices | |
| AU2013344654A1 (en) | Oral transmucosal drug delivery system | |
| LT2793857T (lt) | Vaisto įvedimo technologija | |
| SG11201404454VA (en) | Improvements relating to medicament delivery devices | |
| ZA201505050B (en) | Oral transmucosal delivery of glatiramer acetate | |
| SI2922530T1 (sl) | Formulacije kaspofugin acetata | |
| SG10201609440WA (en) | Multi-additive delivery system | |
| PL2908837T3 (pl) | Kompozycje do dostarczania leku | |
| SG11201405743QA (en) | Liposomal delivery system | |
| GB201319437D0 (en) | Delivery of drugs | |
| EP2891350A4 (en) | CIRCUIT SWITCHING CALL ROUTING | |
| GB201121693D0 (en) | Medicament delivery technology | |
| GB201210511D0 (en) | Parcel delivery solution | |
| AU2012905193A0 (en) | Delivery of substitute content |